|
27 Sep 2019 |
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
|
|
27 Sep 2019 |
Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
|
|
27 Sep 2019 |
Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress
|
|
25 Sep 2019 |
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
|
|
25 Sep 2019 |
Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment
|
|
25 Sep 2019 |
UCB presents UCB0107 anti-Tau immunotherapy Phase I study results at World Movement Disorders Conference
|
|
24 Sep 2019 |
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have Undergone C
|
|
24 Sep 2019 |
Immutep to Receive £4M Milestone Payment From GSK
|
|
24 Sep 2019 |
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis
|
|
23 Sep 2019 |
Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO
|
|
22 Sep 2019 |
CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
|
|
20 Sep 2019 |
2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors
|
|
20 Sep 2019 |
CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
|
|
20 Sep 2019 |
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
|
|
19 Sep 2019 |
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
|
|
19 Sep 2019 |
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%
|
|
18 Sep 2019 |
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis
|
|
17 Sep 2019 |
Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
|
|
17 Sep 2019 |
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy
|
|
17 Sep 2019 |
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
|
|
17 Sep 2019 |
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
|
|
16 Sep 2019 |
Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting
|
|
16 Sep 2019 |
Janssen Submits Application to U.S. FDA Seeking First-in-Class Approval of TREMFYA® (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
|
|
13 Sep 2019 |
Genentech’s Fixed Dose Subcutaneous Combination of Perjeta And Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer
|
|
13 Sep 2019 |
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
|
